Pyridine

Pyridine

SCHEMBL936385

O=C(O)Cl.c1ccncc1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 4/20 0.60
TSHR P16473 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 3/20 0.39
APP P05067 1/20 0.39
GAA P10253 1/20 0.39
HCAR3 P49019 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39
PLOD2 O00469 2/20 0.36
TAAR1 Q96RJ0 1/20 0.36
PLOD3 O60568 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
PLOD1 Q02809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL9851406 1.00 NAPRT (0.60) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL6730524 0.93 NAPRT (0.60) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL360206 0.90 NAPRT (0.56) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL29133271 0.90 NAPRT (0.56) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL4636073 0.89
Pyridine SCHEMBL8916332 0.88 NAPRT (0.53) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL27310910 0.88 NAPRT (0.53) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL367908 0.88 NAPRT (0.53) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL27894846 0.87 NAPRT (0.60) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL5278800 0.86 NAPRT (0.69) NAPRTTSHRTDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2978750-B1 \"SYNTHESIS OF DABIGATRAN\ USV PRIVATE LTD (IN) 2020-03-04 EP claimed
US-9688657-B2 Synthesis of dabigatran USV PRIVATE LIMITED (IN) 2017-06-27 US claimed
US-20160060248-A1 SYNTHESIS OF DABIGATRAN USV PRIVATE LIMITED (IN) 2016-03-03 US claimed
EP-2978750-A2 \"SYNTHESIS OF DABIGATRAN\ USV Limited (IN) 2016-02-03 EP claimed
WO-2014167577-A2 \"SYNTHESIS OF DABIGATRAN\ USV LIMITED (IN) 2014-10-16 WO claimed
US-8212034-B2 Process for preparing rosuvastatin calcium AUROBINDO PHARMA LTD. (IN) 2012-07-03 US claimed
US-20100029940-A1 PROCESS FOR PREPARING ROSUVASTATIN CALCIUM AUROBINDO PHARMA LTD (IN) 2010-02-04 US claimed
CN-100443471-C Chemical synthesis method of 4-amino-3,5,6-trichloropyridine-2-formic acid SICHUAN MIANYANG LIER CHEMICAL (CN) 2008-12-17 CN claimed
WO-2008072078-A1 AN IMPROVED PROCESS FOR PREPARING ROSUVASTATIN CACLIUM AUROBINDO PHARMA LIMITED (IN) 2008-06-19 WO claimed
CN-1923810-A Chemical synthesis method of 4-amino-3,5,6-trichloropyridine-2-formic acid SICHUAN MIANYANG LIER CHEMICAL (CN) 2007-03-07 CN claimed
EP-1015663-A1 CORROSION INHIBITION THROUGH THE USE OF A QUATERNARY PYRIDINE SALT-HYDROCARBON COMBINATION Stanchem Inc. (CA) 2000-07-05 EP claimed
WO-1998033953-A1 CORROSION INHIBITION THROUGH THE USE OF A QUATERNARY PYRIDINE SALT-HYDROCARBON COMBINATION STANCHEM INC. (CA) 1998-08-06 WO claimed
EP-0024382-B1 PIPERIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM af Ekenstam, Bo (SE) 1984-03-07 EP claimed
EP-0024382-A1 Piperidine derivatives, their preparation and pharmaceutical compositions containing them af Ekenstam, Bo (SE) 1981-03-04 EP claimed
JP-1029397-A None JP disclosed
JP-58203995-A None JP disclosed
CN-107108493-B Oxazoline compounds substituted by carbocyclic fused ring systems 巴斯夫欧洲公司 2021-03-23 CN disclosed
US-4072810-A FREE RADICAL CROSSLINKING OF UNSATURATED POLYMERS AND POLYMERIZATION CATALYSTS PENNWALT CORPORATION (US) 1978-02-07 US disclosed
US-3965145-A FREE RADICALS PENNWALT CORPORATION (US) 1976-06-22 US disclosed
US-3963673-A Polymer crosslinking with coupled peroxides PENNWALT CORPORATION (US) 1976-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060248-A1 SYNTHESIS OF DABIGATRAN ESD, F2, PROC NAPRT 739/4885TSHR 2743/4885TDP1 1714/4885
US-20100029940-A1 PROCESS FOR PREPARING ROSUVASTATIN CALCIUM CACNA1E, SLC5A6, QDPR NAPRT 1980/4885TSHR 4457/4885TDP1 4428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.